Date: 2015-07-02
Type of information: Nomination
Compound:
Company: Oncobiologics (USA - NJ)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On July 2, 2015, Oncobiologics announced that Kenneth Bahrt, MD, FACR has joined the company as its Chief Medical Officer. A recognized expert in immunology, he brings over 30 years of clinical and pharmaceutical industry experience in both small molecule and protein therapeutics. Dr. Bahrt previously served as the Vice President of US Medical Affairs at NPS Pharmaceuticals responsible for two orphan products. He was part of the launch team for Natpara, the first replacement hormone therapy for hypoparathyroidism. At Savient Pharmaceuticals, he was SVP and Chief Medical Officer and was the medical lead on the team that obtained European marketing approval for Krystexxa (pegloticase) for the treatment of chronic tophaceous gout. Previously, Dr. Bahrt joined Genentech as part of the Roche acquisition and became the Therapeutic Head of Immunology Medical Affairs responsible for multiple products including Actrema, Rituxan, Xolair, and Pulmozyme. While at Roche, he was the Global Medical Director for Immunology, leading both the US and Global Medical Affairs teams. Dr. Bahrt is a board-certified Internist and Rheumatologist and a Fellow of the American College of Rheumatology. He has been Chairman of the Industry Roundtable and a member of the Board of Directors for the Research and Education Foundation of the American College of Rheumatology. He has authored or co-authored numerous scientific publications. Dr. Bahrt holds a medical degree from Hahnemann University and a bachelor’s degree in biology from Muhlenberg College.
Financial terms:
Latest news:
